Protocol for a Multicentric Cohort Study on Neonatal Screening and Early Interventions for Sickle Cell Disease Among High-Prevalence States of India

<b>Background:</b> Sickle cell disease (SCD) is consequently associated with increased rates of infant and childhood morbidity and mortality. Therefore, early detection is a crucial aspect of managing SCD to mitigate complications and improve health outcomes for SCD children. Neonatal screening is the primary method for identifying newborns with SCD, enabling early diagnosis, family screening, and comprehensive medical care. The protocol presented in this paper describes a study aimed at screening newborns for SCD in high-prevalence SCD states of India to understand the magnitude of the problem and the benefits of early comprehensive care along with the genotypic and phenotypic correlation. <b>Methods:</b> A prospective cohort study will be conducted across seven sites in six states of India (Rajasthan, Odisha, Tamil Nadu, Maharashtra, Madhya Pradesh, and Gujarat), having a high prevalence of SCD. The cord blood or heel prick samples of all the live-born babies delivered within the facilities of selected regions will be collected for screening SCD by HPLC (High-Performance Liquid Chromatography). All the sickle cell homozygous (SS) babies will be confirmed at 6 weeks for Sickle genotype along with cascade screening. Further, SS babies will be followed up from six weeks up to five years of life with initiation of folic acid, antibiotic prophylaxis, and hydroxyurea treatment at appropriate times. <b>Results:</b> The protocol aims to lay the groundwork for the smooth implementation of newborn screening programs and effective follow-up strategies. <b>Conclusions:</b> It will pave the way for developing a strategic framework for implementing newborn screening programs for haemoglobinopathies in India.

Authors

Institutions

Publication Details

Journal
Diagnostics
Published
2025-03-14
DOI
https://doi.org/10.3390/diagnostics15060730
Citations
5
Primary Topic
Hemoglobinopathies and Related Disorders
Type
article
Field-Weighted Citation Impact
8.13

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Protocol for a Multicentric Cohort Study on Neonatal Screening and Early Interventions for Sickle Cell Disease Among High-Prevalence States of India

Kapilkumar Dave, Anna Salomi Kerketta, Suchitra Surve, Anita Nadkarni et al.
5 citations
Diagnostics
Hemoglobinopathies and Related Disorders
8.13
article

Protocol for a Multicentric Cohort Study on Neonatal Screening and Early Interventions for Sickle Cell Disease Among High-Prevalence States of India

Kapilkumar Dave, Anna Salomi Kerketta, Suchitra Surve, Anita Nadkarni, Manisha Rajan Madkaikar, Harpreet Kaur, Apoorva Pandey, Prabhakar Kedar, Mahendra Thakor, Shrey Desai, Suman Sundar Mohanty, Ragini Kulkarni, Rajasubramaniam Shanmugam, Saritha Nair, Kalpita Gawit, Lakshmana Bharathi Ramasamy, Oshin Warerkar, Nithin Rajamani
article en
5 citations

Abstract

<b>Background:</b> Sickle cell disease (SCD) is consequently associated with increased rates of infant and childhood morbidity and mortality. Therefore, early detection is a crucial aspect of managing SCD to mitigate complications and improve health outcomes for SCD children. Neonatal screening is the primary method for identifying newborns with SCD, enabling early diagnosis, family screening, and comprehensive medical care. The protocol presented in this paper describes a study aimed at screening newborns for SCD in high-prevalence SCD states of India to understand the magnitude of the problem and the benefits of early comprehensive care along with the genotypic and phenotypic correlation. <b>Methods:</b> A prospective cohort study will be conducted across seven sites in six states of India (Rajasthan, Odisha, Tamil Nadu, Maharashtra, Madhya Pradesh, and Gujarat), having a high prevalence of SCD. The cord blood or heel prick samples of all the live-born babies delivered within the facilities of selected regions will be collected for screening SCD by HPLC (High-Performance Liquid Chromatography). All the sickle cell homozygous (SS) babies will be confirmed at 6 weeks for Sickle genotype along with cascade screening. Further, SS babies will be followed up from six weeks up to five years of life with initiation of folic acid, antibiotic prophylaxis, and hydroxyurea treatment at appropriate times. <b>Results:</b> The protocol aims to lay the groundwork for the smooth implementation of newborn screening programs and effective follow-up strategies. <b>Conclusions:</b> It will pave the way for developing a strategic framework for implementing newborn screening programs for haemoglobinopathies in India.

DiagnosticsVol. 15(6)
National Institute for Research in Reproductive Health (IN), Indian Council of Medical Research (IN), National Institute for Research in Tribal Health (IN), ICMR - National Institute of Immunohaemotology (IN), Regional Medical Research Centre (IN), Society for Education Welfare and Action Rural (IN), National Institute for Implementation Research on Non-Communicable Diseases (IN)
Indian Council of Medical Research
Good health and well-being
Openalex Percentile: Top 3%
Hemoglobinopathies and Related Disorders
8.13
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.